Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain

References

• O’Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2017;15(7):926–957. doi:10.6004/jnccn.2017.0116
   PubMed Web of Science ®Google Scholar
• Infante MS, MÁ P, Hernández-Rivas JÁ. Alteraciones moleculares en leucemia mieloide aguda y sus implicaciones clínicas y terapéuticas [Molecular alterations in acute myeloid leukemia and their clinical and therapeutical implications]. Med Clin (Barc). 2018. doi:10.1016/j.medcli.2018.05.002
   PubMed Web of Science ®Google Scholar
• Fey MF, Buske C; Group on behalf of the EGW. Acute myeloblastic leukaemias in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(suppl_6):vi138–vi143. doi:10.1093/annonc/mdt32023970018
   PubMedGoogle Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-73319627895058
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Midostaurin. Summary of Product Characteristics. Rydapt 25mg Soft Capsules. Available from: https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Accessed August 6, 2019.
   Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1056/NEJMoa161435928644114
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. Propuesta de guía para la evaluación económica aplicada a las tecnologías sanitarias. Gac Sanit. 2010;24:154–170. doi:10.1016/j.gaceta.2009.07.01119959258
   PubMed Web of Science ®Google Scholar
• Ortega Eslava A, Marín Gil R, Fraga Fuentes MD, López-Briz E, Puigventós Latorre F. Guía De Evaluación Económica E Impacto Presupuestario En Los Informes De Evaluación De Medicamentos. Guía Práctica Asociada Al Programa MADRE V 4.0. Madrid: SEFH ; 2016 ISBN: 978-84-617-6757-1
   Google Scholar
• National Institute of Health and Care Excellence. Midostaurin for Untreated Acute Myeloid Leukaemia. 2018 Available from:  https://www.nice.org.uk/guidance/ta523. Accessed August 6, 2019.
   Google Scholar
• Pan-Canadian Oncology Drug Review Final Economic Guidance Report Midostaurin (Rydapt) for Acute Myeloid Leukemia; 2017 Available from: www.cadth.ca/pcodr. Accessed 86, 2019.
   Google Scholar
• Haute Autorité de Santé. Available from: https://www.has-sante.fr/upload/docs/application/pdf/2018-10/rydapt-lam_22052018_avis_efficience.pdf. Accessed 86, 2019.
   Google Scholar
• Insituto Nacional de Estadística. Mortalidad por sexo y edad. 2018.
   Google Scholar
• Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol. 1998;100(4):629–636. doi:10.1046/j.1365-2141.1998.00635.x9531327
   PubMed Web of Science ®Google Scholar
• Batty N, Yin Y, Wetzler M. Decitabine is more cost effective than cytarabine and daunorubicin in elderly acute myeloid leukemia patients. J Cancer Res Ther. 2014;2(4):68–73. doi:10.14312/2052-4994.2014-9
   Google Scholar
• Leunis A, Redekop WK, Uyl-de Groot CA, Löwenberg B. Impaired health-related quality of life in acute myeloid leukemia survivors: a single-center study. Eur J Haematol. 2014;93(3):198–206. doi:10.1111/ejh.1232424673368
   PubMed Web of Science ®Google Scholar
• Crott R, Briggs A. Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. Eur J Heal Econ. 2010;11(4):427–434. doi:10.1007/s10198-010-0233-7
   PubMed Web of Science ®Google Scholar
• Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant. 2011;47:473. doi:10.1038/bmt.2011.10721602898
   PubMedGoogle Scholar
• Consejo General de Colegios Oficiales de Farmacéuticos (CGCOF). Consejo General de Colegios Oficiales de Farmacéuticos. Base de datos del conocimiento sanitario. 2016.
   Google Scholar
• Ministerio de Sanidad Consumo y Bienestar Social (MSCBS). Real Decreto-Ley 8/2010 De 20 De Mayo, Por El Que Se Adoptan Medidas Extraordinarias Para La Reducción Del Déficit Público. Boletín Oficial del Estado. 2010.
   Google Scholar
• Gisbert R, Brosa M Base de datos de costes sanitarios y ratios coste-efectividad españoles: eSalud [Internet]. Available from: http://esalud.oblikue.com/. Accessed November 2017.
   Google Scholar
• Ministerio de Sanidad Servicios Sociales e Igualdad (MSSSI). Conjunto Mínimo Básico de Datos (CMBD).
   Google Scholar
• Rashidi A, Weisdorf DJ, Bejanyan N. Treatment of relapsed/refractory acute myeloid leukaemia in adults. Br J Haematol. 2018;181(1):27–37. doi:10.1111/bjh.1507729318584
   PubMed Web of Science ®Google Scholar
• Tremblay G, Dolph M, El Ouagari K, Brandt P, Forsythe A. Cost-Effectiveness Analysis of Midostaurin (MIDO) With Standard of Care (SOC) for Acute Myeloid Leukemia (AML) in Canada. Value Heal. 2018;21:S28–S29. doi:10.1016/j.jval.2018.04.180
   Web of Science ®Google Scholar
• Tremblay G, Dolph M, Patel S, Brandt P, Forsythe A. Cost-effectiveness analysis of midostaurin (MIDO) with Standard Chemotherapy (SOC) for Acute Myeloid Leukemia (AML) in the United Kingdom (UK). Value Heal. 2017;20(9):A399. doi:10.1016/j.jval.2017.08.005
   Web of Science ®Google Scholar
• Brosa M, García Del Muro X, Mora J, et al. Orphan drugs revisited: cost–effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):331–340. doi:10.1586/14737167.2015.97237825354299
   PubMed Web of Science ®Google Scholar
• Núñez M, Gil B, Sacristán JA, Dilla T. Analysis of orphan drugs marketed in spain during the period 2010-2015: epidemiological, clinical and economic characteristics. Health Econ Outcome Res Open Access. 2017;3:140. doi:10.4172/2471-268X.1000140
   Google Scholar
• Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141–145. doi:10.1093/heapol/czw09627452949
   PubMed Web of Science ®Google Scholar
• Sacristán JA, Oliva J, Del LJ, Prieto L, Pinto JL. ¿Qué es una tecnología sanitaria eficiente en España? Gac Sanit. 2002;16(4):334–343. doi:10.1016/S0213-9111(02)71933-X12113733
   PubMedGoogle Scholar
• Crespo C, Moreno E, Sierra J, Serip S, Rubio M. Cost-effectiveness analysis of azacitidine in the treatment of high-risk myelodysplastic syndromes in Spain. Health Econ Rev. 2013;3:28. doi:10.1186/2191-1991-3-2824314138
   PubMedGoogle Scholar
• Casado LF, Hernández JÁ, Jarque I, Echave M, Casado MA, Castro A. Cost-utility analysis of idelalisib in combination with rituximab in relapsed or refractory chronic lymphocytic leukaemia. Eur J Haematol. 2017;100(3):264–272. doi:10.1111/ejh.13007
   Web of Science ®Google Scholar